

14 October 2026

Date of AGM and Closing Date for Director Nominations

Argent BioPharma Limited (ASX: RGT) advises, in accordance with ASX Listing Rule 3.13.1, that the Company's Annual General Meeting is scheduled to be held on Friday, 20 November 2026.

The closing date for receipt of nominations for persons wishing to be considered for election as a director is 5.00pm (WST) on Wednesday, 21 October 2026. Nominations must be received at the Company's registered office by this time.

— Ends —

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma

Roby Zomer

Chairman

+61 8 6555 2950

info@argentbiopharma.com

Argent BioPharma

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Limited (ASX: RGT) is a revenue-generating immune science and specialty biopharmaceutical company focused on the development and commercialisation of technologies across immune modulation, inflammatory disease and precision drug delivery.

The Company's portfolio combines internally developed pharmaceutical programmes, owned intellectual property, licensed commercialisation rights, early-stage biologic technologies, commercial products, manufacturing capabilities and strategic licensing partnerships.

Argent BioPharma's strategy is to concentrate internal development resources on differentiated immune modulation technologies while using commercialisation, manufacturing and strategic partnerships to create additional routes to long-term value.